The company emphasised that it is ready to meet the growing demand for drug-device combinations and biologics, with ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but ...

LCMC Health officials announced the activation of their code grey plan at hospitals across the Greater New Orleans region.

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 ...

A woman was injured when she fell out of a vehicle on the interstate. Your urine can tell you a lot about your health. A ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

The long-term prospects for the company are evolving with product approvals in China, build-up of consumer healthcare franchise, and a biosimilar pipeline.

Revlimid, which has arguably been the single biggest growth driver for Dr Reddy's in recent years, is set to go off patent in ...

A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.

Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...

IST, the barometer index, the S&P BSE Sensex, shed 45.42 points or 0.07% to 76,474.96. The Nifty 50 index fell 20.60 points or 0.09% to 23,184.75.